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ScienceDirectThe RAS/RAF/MEK/MAPK kinase pathway has been
extensively studied for more than 25 years, yet we continue to
be puzzled by its intricate dynamic control and plasticity.
Different spatiotemporal MAPK dynamics bring about distinct
cell fate decisions in normal vs cancer cells and developing
organisms. Recent modelling and experimental studies
provided novel insights in the versatile MAPK dynamics
concerted by a plethora of feedforward/feedback regulations
and crosstalk on multiple timescales. Multiple cancer types and
various developmental disorders arise from persistent
alterations of the MAPK dynamics caused by RAS/RAF/MEK
mutations. While a key role of the MAPK pathway in multiple
diseases made the development of novel RAF/MEK inhibitors a
hot topic of drug development, these drugs have unexpected
side-effects and resistance inevitably occurs. We review how
RAF dimerization conveys drug resistance and recent
breakthroughs to overcome this resistance.
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Introduction
The mitogen-activated protein kinase (MAPK) cascades
have been in the limelight of research for over 25 years due
to their involvement in cell proliferation, differentiation,
survival/apoptosis, and motility. This scientific interest is
also practical, because deregulation of MAPK signalling is
a feature of major human diseases and developmental
disorders [1,2]. The MAPK signalling cascades arewww.sciencedirect.com activated by a plethora of external cues through a multi-
tude of membrane receptors, including receptor tyrosine
kinases (RTKs) and G-protein coupled receptors
(GPCRs). All MAPK cascades have the evolutionary con-
served three-tier architecture where kinases sequentially
phosphorylate and activate each other, whereas phospha-
tases dephosphorylate these kinases [3]. The initiating
kinases (such as RAF1/CRAF and BRAF) in the extracel-
lular regulated kinase 1/2 (ERK1/2) cascade are commonly
activated by RAS small G-proteins. The components of
the RAS/RAF/MEK/ERK cascade are frequently mutated
in cancer [4] and are hot targets for an ever increasing
number of anti-cancer drugs [5,6].
Although the RAS/RAF/MEK/ERK pathway has a pre-
dominantly linear architecture, RAS and ERK are sig-
nalling hubs that have tens and hundreds of effectors and
substrates, respectively. Changes in these interactions
can dramatically change the ERK cascade temporal dy-
namics [7]. Different ERK dynamics were shown to
trigger distinct cell decisions. For instance, in rat adrenal
pheochromocytoma PC12 cells a transient activation of
ERK induced by epidermal growth factor (EGF) results
in cell proliferation, whereas sustained ERK activation
by nerve growth factor (NGF) induces differentiation [8].
Subsequently, Bastiaens and colleagues showed that
distinct cell decisions are explained by dynamic changes
in the ERK cascade topology where EGF stimulation
elicited negative feedback, whereas NGF induced posi-
tive feedback, imposed on the backbone of the same
three-tier cascade structure [9]. Yet, recently Pertz and
colleagues demonstrated that repeated 3 min pulses of
low EGF concentration resulted in prolonged ERK acti-
vation and PC12 cell differentiation, whereas pulses of
high EGF induced a more transient ERK response and
PC12 cell proliferation similar to sustained EGF stimu-
lation [10]. The fact that the ERK cascade inputs of
different frequency and amplitude rewire cell fate raised
intriguing questions about the design and timescales of
multiple feedforward and feedback regulations in the
ERK network. Answering these questions requires a
careful probing of the RTK/RAS/ERK network circuitry,
uncovering timescales of major regulations, and the
use of computational models. Here we present a brief
overview of the current research efforts in the field,
emphasizing a combined use of modelling and experi-
ments as a tool to advance both the fundamental under-
standing of the control of ERK signalling and therapeutic
applications.Current Opinion in Structural Biology 2016, 41:151–158
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A simplified diagram of feedforward and feedback regulation of the
RTK/RAS/ERK network activated by EGF and NGF in PC12 cells.
Modified from Ref. [10].Versatile ERK dynamics: adaptive and
sustained signalling, switches and oscillations
on different timescales.
In many cells, the RAS/ERK cascade exhibits a transient,
adaptive response to growth factor (GF) stimulation due
to negative feedback loops from ERK to SOS and BRAF/
CRAF, and the negative transcriptional feedback via
ERK-induced expression of the DUSP family phospha-
tases on a longer timescale. However in other cells, the
ERK response is sustained indicating that positive feed-
back and feedforward regulations reverse the effect of
multiple negative feedbacks [11]. Positive feedback loops
can also induce switch-like, bistable responses, where
there is a threshold stimulus magnitude, and ERK is
active until the stimulus decreases to much lower than
threshold nearly basal values [9,12].
A main role of negative feedback is to confer resistance to
perturbations of cascade components within the feedback
loop. Due to several negative feedbacks, the ERK cas-
cade can operate as a negative feedback amplifier, and
this circuitry resists MEK inhibition by anti-cancer drugs
[13]. When a negative feedback becomes too strong, it
induces damped or sustained oscillations [14]. A combi-
nation of positive feedforward regulations by RTKs and
positive and negative feedbacks can explain the ERK
oscillations observed on remarkably different timescales
from minutes to several hours [10,15,16].
Mathematical modelling helps to elucidate the intricate
network dynamics [17]. Recently, the feedforward and
feedback regulation of the RTK/RAS/ERK network and
the dynamics of ERK responses were probed in live single
PC12 cells using microfluidic devices to deliver GF input
stimulation with precisely defined kinetics [10]. Whereas
sustained EGF/NGF stimulation largely confirmed pre-
vious observations (while uncovering a remarkable het-
erogeneity of signalling in individual cells), ERK
responses to GF pulses of different frequency and ampli-
tude showed unexpected signalling and biological out-
comes. Mathematical modelling proved that known
negative and positive feedback regulations could not
explain the observed ERK dynamics. For instance, an
EGF stimulatory regime of 3 min pulses/10 min intervals
between pulses led to successive ERK pulses where the
amplitude decayed much less for low than for high EGF
concentrations. Since the ERK activity peaks in response
to the initial EGF pulse were identical for both low and
high EGF doses, ERK-induced negative feedbacks alone
could not account for these observations. A dynamic
model recapitulated these observation assuming that
the negative ERK influence must be modulated by a
feedforward signal from the EGF receptor, which was
differentially activated by low and high EGF doses [10].
A high-dosage, single NGF pulse of 10 min induced
sustained ERK activity in a cell subpopulation, suggestingCurrent Opinion in Structural Biology 2016, 41:151–158 the presence of bistability brought about by a positive
feedback from ERK, as previously reported [9]. In con-
trast, short 3 min NGF pulses of both high and low doses,
and low dose 10 min NGF pulse elicited transient, adap-
tive ERK activity profiles throughout the cell population.
This implies a slightly delayed and threshold activation of
NGF-evoked positive feedback that occurred only if ERK
activity exceeds certain levels of amplitude and duration.
Since the first peak-response of NGF was similar for all
pulsed NGF stimulation conditions, the data also sug-
gested the existence of additional feedforward regulation
of the ERK positive feedback strength [10]. Figure 1
illustrates a kinetic scheme of a minimal mathematical
model that was able to reproduce all these experimental
observations, including heterogeneity of responses, which
was more pronounced for NGF due to positive feedback
from ERK.
Oncogenic alterations in RAS/RAF/MEK/ERK
signalling
Many human cancers present hyperactivation of the
MAPK pathway, most commonly through mutations in
RAS, BRAF, CRAF, or MEK1/2 [4]. Components of
this pathway are therefore attractive targets for drug
development [5,6,18].
Germline mutations in genes encoding MAPK pathway
components are associated with a group of developmental
disorders known as RASopathies or RAS/MAPK syn-
dromes [19,20]. Biochemical studies of these mutants
as well as structural analysis and network-level datawww.sciencedirect.com
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quantitatively, rather than qualitatively, different com-
pared to cancer-related mutations [1].
About 30% of all human cancers, including about 90% of
pancreatic cancer and 45% of colorectal cancer cases,
present activating mutations in RAS family genes (H-
RAS, K-RAS, and N-RAS) [21], with K-RAS being the
most frequently mutated isoform [22]. Since the discov-
ery of RAS as an oncogene over 30 years ago [23,24,25,26],
no clinically effective inhibitor has yet been developed,
giving RAS a reputation as ‘undruggable’. Recently,
however, a renewed interest in RAS as drug target has
arisen [27,28,29]. Promising novel approaches include
targeting the RAS-SOS complex [30,31,32], inhibiting
the interaction with downstream effectors [33], interfer-
ing with membrane localization [34], and the develop-
ment of mutation-specific small molecule inhibitors
[35,36]. A novel small molecule, Rigosertib, was able to
inhibit MAPK pathway activation through interaction
with the RAS-binding domains (RBDs) of RAS-effector
proteins, including RAF [37]. Rigosertib has entered
clinical phase 3 studies validating the strategy of targeting
protein-protein interactions as a viable approach to target
proteins that previously were considered ‘undruggable’.
Among the three RAF kinase family members, BRAF is
the most frequently mutated isoform in human cancers
[4,38], with particular high prevalence of mutations
(>50%) in melanoma [39] and papillary thyroid carci-
noma [40]. Over 50 mutations have been identified in
BRAF — related to cancer and RASopathies — most of
which are located in the kinase domain (Figure 2)
[4,41]. Characterization of 22 oncogenic BRAF
mutants revealed that the majority of these directly
increase BRAF kinase activity, while others activate
ERK signalling through enhanced dimerization with
and transactivation of wildtype CRAF [42].
BRAF has become an important therapeutic target in
cancer therapy [18,43]. While small molecules targeting
BRAF are ATP-competitive inhibitors, they can employ
different mechanisms: Class I inhibitors (e.g. Vemurafe-
nib/PLX4032) recognize the active (‘DFG-in’) conforma-
tion [44], whereas class II inhibitors (e.g. Sorafenib/BAY-
439006) bind to and stabilize the inactive (‘DFG-out’)
conformation [42]. As 98% of BRAF mutations are found
at position V600, with V600E being the most common one
[41], mutation-selective BRAF inhibitors such as
Vemurafenib [44,45] and Dabrafenib/GSK2118436 [46]
were developed. RAF inhibitor treatment initially leads
to high response rates in patients with BRAF mutant
melanoma, but drug resistance develops within 6–9
months in the majority of patients [47]. Different mech-
anisms have been described (reviewed in [48]), most of
which involve reactivation of the MAPK pathway. These
include secondary mutations in N-RAS [49] or MEK1www.sciencedirect.com [50], a BRAF(V600E) splice variant with enhanced di-
merization [51], the expression of an alternative MEK
kinase [52], or overexpression of RAS, BRAF, CRAF or
RTKs [47]. In addition, other cellular processes, includ-
ing TGFb signalling, chromatin modifying enzymes, and
the Mediator complex, have recently been linked to drug
resistance in high-throughput screens and could possibly
lead to novel therapeutic strategies [53,54,55,56].
While less common, activating mutations in MEK1 and
MEK2 occur in several types of cancer, including mela-
noma [57] and lung adenocarcinoma [58]. MEK1 and
MEK2 mutations also contribute to drug resistance to
RAF and MEK inhibition in BRAF mutant melanoma
[50,59,60,61,62]. While allosteric MEK inhibitors have
suffered from limited clinical success, their combination
with RAF inhibitors (Trametinib/GSK1120212 or Cobi-
metinib/GDC-0973 with BRAF inhibitors Dabrafenib or
Vemurafenib) has abolished the side effects of therapy
induced skin tumours, delayed drug resistance, and im-
proved survival in patients with BRAF mutant melanoma
[63,64]. Further inhibitors are currently in development
and clinical trials [65].
Why kinase dimerization conveys drug
resistance: thermodynamics has the answer
Targeted cancer therapies are hampered by intrinsic and
acquired drug resistance. As mentioned, although ATP-
competitive RAF inhibitors are used in the clinic, these
drugs ‘paradoxically’ activate the ERK pathway, especial-
ly in BRAF wild-type cells [41,66]. A culprit of this
unexpected activation is heterodimerization of RAF
kinases. In RAF dimers, a kinase-dead or inhibited
RAF protomer allosterically activates the other inhibi-
tor-free protomer, driving ERK signalling. Paradoxical
ERK activation by RAF inhibitors in melanoma patients
causes both drug resistance and clinical side-effects,
including the frequent incidence of keratoacanthomas
and squamous-cell carcinomas [5]. Recent efforts have
produced RAF inhibitors that evade this paradoxical ERK
activation [67,68], although the reason remained obscure
why within RAF dimers only one protomer binds drug.
Kholodenko showed that drug resistance caused by ki-
nase dimerization results from fundamental thermody-
namic principles [69]. The inhibitor binding to one kinase
monomer allosterically facilitates its dimerization with a
free monomer. In this constellation, one protomer that is
drug-bound allosterically activates the other, drug-free
protomer. Mathematical models show the significant ac-
cumulation of such dimers that harbour drug-bound and
free protomers are active and convey resistance [69].
Thermodynamic laws further imply that two protomers
in a dimer may acquire different drug affinities. This
emergence of different drug affinities between monomers
and protomers in a kinase dimer has long been enigmatic.
Using different RAF mutants it was shown that binding ofCurrent Opinion in Structural Biology 2016, 41:151–158
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Oncogenic mutation sites in the BRAF kinase domain. (a) 22 residues in BRAF which are frequently mutated in cancer [4,41] were mapped
onto the structure of the BRAF kinase domain (grey). Important functional elements are highlighted: N-terminal acidic (NtA) motif (cyan), P-loop
(orange), and activation segment (crimson). Residues with activating mutations are shown in green, residues with kinase-impaired mutations in
red. Mutations in residues in blue can be either activating or kinase-impaired, while purple-coloured residues have not yet been characterized in
the literature. (b) Locations of oncogenic mutations sites (as in panel a) in the two protomers (backbone in grey and light blue, respectively) of a
BRAF kinase homodimer. The PDB file was kindly provided by Dr. Rosta [73].RAF inhibitor to one protomer in a dimer commonly
reduces the affinity for binding the drug to the second
protomer in the dimer [70]. Instructively, mathematical
models show that while for any inhibitor that facilitates
kinase dimerization, the first inhibitor molecule always
binds to a dimer with the lower affinity than to a monomer
conferring resistance, it is still thermodynamically feasi-
ble that the affinities of the first and the second drug
molecule binding to protomers in a dimer will be equal
[69]. Confirming these model-based predictions, only one
inhibitor, BGB659, from a large panel of currently used
RAF inhibitors showed comparable binding affinities for
both protomers in a RAF dimer [70]. However, as predicted
by the model [69], BGB659 also showed paradoxicalCurrent Opinion in Structural Biology 2016, 41:151–158 activation of the ERK cascade, most pronouncedly in
RAS-mutant melanoma cell lines [70]. Likewise, this
model predicted that pan-RAF inhibitors that bind equally
well to CRAF and BRAF are much more effective than
specific BRAF inhibitors [69], which is in line with recent
experimental findings [67,71]. Peng et al. described a new
pan-RAF inhibitor, LY3009120, that was effective against
RAS or BRAF mutant tumour cells in vitro and in vivo while
showing a minimal paradoxical ERK pathway activation,
despite increasing RAF dimerization [71]. Given the low
half-maximal inhibitory dose, IC50 of 5–10 nM, computer
simulations [69] show that following paradoxical pathway
activation at very low doses, a further increase in
LY3009120 effectively inhibits the total RAF and ERKwww.sciencedirect.com
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Two inhibitors against the same target, RAF kinases, can abolish drug resistance. Each inhibitor, I1 or I2, is ineffective, since the accumulation of
active dimers that harbour drug-bound and free RAF protomers (RAFI1-RAF and RAFI2-RAF) drives resistance. Allosteric interactions between
inhibitors and RAF dimer result in the preferable binding of two different inhibitors to the same dimer, converting partially inhibited into fully-
inhibited dimers. As a consequence, these two drugs that were ineffective on their own abolish resistance when combined.activities, which explains the data reported by Peng
et al. [71].
Computational models of protein and inhibitor interac-
tions not only predict drug dose-response dependencies
but also suggest new ways to overcome drug resistance
[69]. These models demonstrate that two inhibitors,
aimed at the same kinase target and ineffective on their
own, can abolish drug resistance when combined
(Figure 3). This unexpected finding is an elegant dem-
onstration how dynamic systems biology models can
streamline drug development [69].
Outlook
While there is abundant evidence that signalling dynam-
ics can regulate cell fate decisions, a mechanistic under-
standing is only emerging. New techniques, such as
biosensors and the use of microfluidics, allow the con-
trolled variation of growth factor input signals and close to
real time readout of biochemical responses on timescales
that deeply probe dynamic signal processing. The results
from these studies showed that intricate arrays of feed-
back and feedforward loops orchestrate the response
dynamics. Excitingly, understanding how response dy-
namics are generated, we now can start to engineer
desired responses by artificially modulating physiological
stimuli [10]. This ability could find broad applications in
cell engineering or regenerative medicine, where we
try to control cell proliferation and differentiation.www.sciencedirect.com Another important insight emerging from studying sig-
nalling dynamics was the explanation for the conundrum
that dimerization can confer drug resistance to kinase
inhibitors. Borne out with RAF kinase as paradigm, this
mechanism likely is widespread. Numerous kinases are
allosterically regulated by dimerization. For instance, in
the case of Janus kinases (JAKs) dimerization induced
resistance to JAK inhibitors in patients with myeloprolif-
erative tumours [72]. Having recognized the mechanism
enables the design of new inhibitors or inhibitor combi-
nations that overcome this type of resistance.
Conflict of interest
The authors declare that they have no conflicts of interest.
Acknowledgements
This work was supported by the European Union FP7 grants ‘‘PRIMES’’
(No. 278568) and ‘‘SynSignal’’ (No. 613879) and H2020 SmartNanoTox
(No. 686098). We would like to thank Drs. Fey and Nguyen for their help
with the preparation of graphical material.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Kiel C, Serrano L: Structure-energy-based predictions and
network modelling of RASopathy and cancer missense
mutations. Mol Syst Biol 2014, 10:727.Current Opinion in Structural Biology 2016, 41:151–158
156 Multi-protein assemblies in signaling2. Jindal GA, Goyal Y, Burdine RD, Rauen KA, Shvartsman SY:
RASopathies: unraveling mechanisms with animal models. Dis
Model Mech 2015, 8:769-782.
3.

Lim B, Dsilva CJ, Levario TJ, Lu H, Schupbach T, Kevrekidis IG,
Shvartsman SY: Dynamics of inductive ERK signaling in the
Drosophila embryo. Curr Biol 2015, 25:1784-1790.
Spatiotemporal patterns of ERK signaling that induced cell fates in
developing Drosophila embryos were quantitative analyzed.
4.

Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N,
Boutselakis H, Ding M, Bamford S, Cole C, Ward S et al.: COSMIC:
exploring the world’s knowledge of somatic mutations in
human cancer. Nucleic Acids Res 2015, 43:D805-D811.
See comment to Ref. 39.
5. Rahman MA, Salajegheh A, Smith RA, Lam AK: BRAF inhibitors:
from the laboratory to clinical trials. Crit Rev Oncol Hematol
2014, 90:220-232.
6.

Caunt CJ, Sale MJ, Smith PD, Cook SJ: MEK1 and MEK2
inhibitors and cancer therapy: the long and winding road. Nat
Rev Cancer 2015, 15:577-592.
An overview of the effects of allosteric MEK1/MEK2 inhibitors in the
context of intra-cascade regulatory connections and crosstalk with other
pathways.
7. Kholodenko BN, Hancock JF, Kolch W: Signalling ballet in space
and time. Nat Rev Mol Cell Biol 2010, 11:414-426.
8. Marshall CJ: Specificity of receptor tyrosine kinase signaling:
transient versus sustained extracellular signal-regulated
kinase activation. Cell 1995, 80:179-185.
9. Santos SD, Verveer PJ, Bastiaens PI: Growth factor-induced
MAPK network topology shapes Erk response determining
PC-12 cell fate. Nat Cell Biol 2007, 9:324-330.
10.

Ryu H, Chung M, Dobrzynski M, Fey D, Blum Y, Lee SS, Peter M,
Kholodenko BN, Jeon NL, Pertz O: Frequency modulation of
ERK activation dynamics rewires cell fate. Mol Syst Biol 2015,
11:838.
Shown that not only NGF but also EGF given in 3 min pulses of low doses
result in prolonged ERK activation and cell differentiation similar to NGF
stimulation. A dynamic model suggested novel regulatory motif where
feedforward regulation affects feedback.
11. Nagashima T, Inoue N, Yumoto N, Saeki Y, Magi S, Volinsky N,
Sorkin A, Kholodenko BN, Okada-Hatakeyama M: Feedforward
regulation of mRNA stability by prolonged extracellular signal-
regulated kinase activity. FEBS J 2015, 282:613-629.
12. Nguyen LK, Kholodenko BN: Feedback regulation in cell
signalling: lessons for cancer therapeutics. Semin Cell Dev Biol
2015 http://dx.doi.org/10.1016/j.semcdb.2015.09.024.
13. Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V,
Gilbert D, Calder M, Pitt A, Kholodenko B, Kolch W: The
mammalian MAPK/ERK pathway exhibits properties of
a negative feedback amplifier. Sci Signal 2010, 3:
ra90.
14. Kholodenko BN: Negative feedback and ultrasensitivity can
bring about oscillations in the mitogen-activated protein
kinase cascades. Eur J Biochem 2000, 267:1583-1588.
15. Albeck JG, Mills GB, Brugge JS: Frequency-modulated pulses
of ERK activity transmit quantitative proliferation signals. Mol
Cell 2013, 49:249-261.
16.

Sparta B, Pargett M, Minguet M, Distor K, Bell G, Albeck JG:
Receptor level mechanisms are required for epidermal growth
factor (EGF)-stimulated extracellular signal-regulated kinase
(ERK) activity pulses. J Biol Chem 2015, 290:24784-24792.
Stimulation with constant EGF induced quasi-periodic, discrete pulses of
ERK activity detected in single cells, whereas constant NGF stimulation of
cells stably transfected with TrkA led to sustained ERK activation with no
detectable oscillations.
17. Kholodenko BN: Cell-signalling dynamics in time and space.
Nat Rev Mol Cell Biol 2006, 7:165-176.
18. Samatar AA, Poulikakos PI: Targeting RAS-ERK signalling in
cancer: promises and challenges. Nat Rev Drug Discov 2014,
13:928-942.Current Opinion in Structural Biology 2016, 41:151–158 19. Aoki Y, Niihori T, Inoue S, Matsubara Y: Recent advances in
RASopathies. J Hum Genet 2016, 61:33-39.
20. Rauen KA: The RASopathies. Annu Rev Genomics Hum Genet
2013, 14:355-369.
21. Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-
activated protein kinase cascade for the treatment of cancer.
Oncogene 2007, 26:3291-3310.
22. Prior IA, Lewis PD, Mattos C: A comprehensive survey of Ras
mutations in cancer. Cancer Res 2012, 72:2457-2467.
23. Der CJ, Krontiris TG, Cooper GM: Transforming genes of human
bladder and lung carcinoma cell lines are homologous to the
ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl
Acad Sci U S A 1982, 79:3637-3640.
24. Parada LF, Tabin CJ, Shih C, Weinberg RA: Human EJ bladder
carcinoma oncogene is homologue of Harvey sarcoma virus
ras gene. Nature 1982, 297:474-478.
25. Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M: T24
human bladder carcinoma oncogene is an activated form of
the normal human homologue of BALB- and Harvey-MSV
transforming genes. Nature 1982, 298:343-347.
26. Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M,
Wigler M: Activation of the T24 bladder carcinoma
transforming gene is linked to a single amino acid change.
Nature 1982, 300:762-765.
27. Ledford H: Cancer: The Ras renaissance. Nature 2015, 520:
278-280.
28. Ryan MB, Der CJ, Wang-Gillam A, Cox AD: Targeting -mutant
cancers: is ERK the key? Trends Cancer 2015, 1:183-198.
29. Stephen Andrew G, Esposito D, Bagni Rachel K, McCormick F:
Dragging Ras back in the ring. Cancer Cell 2014, 25:272-281.
30. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ,
Fauber BP, Pan B, Malek S, Stokoe D et al.: Small-molecule
ligands bind to a distinct pocket in Ras and inhibit SOS-
mediated nucleotide exchange activity. Proc Natl Acad Sci U S
A 2012, 109:5299-5304.
31. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG,
Lee T, Rossanese OW, Fesik SW: Discovery of small molecules
that bind to K-Ras and inhibit Sos-mediated activation. Angew
Chem Int Ed Engl 2012, 51:6140-6143.
32. Winter JJ, Anderson M, Blades K, Brassington C, Breeze AL,
Chresta C, Embrey K, Fairley G, Faulder P, Finlay MR et al.: Small
molecule binding sites on the Ras:SOS complex can be
exploited for inhibition of Ras activation. J Med Chem 2015,
58:2265-2274.
33. Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L,
Sugimoto T, Ijiri Y, Takeda A et al.: In silico discovery of small-
molecule Ras inhibitors that display antitumor activity by
blocking the Ras-effector interaction. Proc Natl Acad Sci U S A
2013, 110:8182-8187.
34. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A,
Hoffmann M, Hahn SA, Triola G, Wittinghofer A, Bastiaens PI et al.:
Small molecule inhibition of the KRAS-PDEdelta interaction
impairs oncogenic KRAS signalling. Nature 2013 http://
dx.doi.org/10.1038/nature12205.
35. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM: K-Ras(G12C)
inhibitors allosterically control GTP affinity and effector
interactions. Nature 2013, 503:548-551.
36. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG,
Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T et al.:
Therapeutic targeting of oncogenic K-Ras by a covalent
catalytic site inhibitor. Angew Chem Int Ed Engl 2014, 53:
199-204.
37.

Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ,
Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR et al.:
A small molecule RAS-mimetic disrupts RAS association with
effector proteins to block signaling. Cell 2016, 165:643-655.
A small molecule, Rigosertib disrupts the RAS-RAF interaction and
thereby inhibits MAPK signalling and RAS-mediated transformation.www.sciencedirect.com
MAPK kinase dynamics regulate cell fate decisions Rauch et al. 15738. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S,
Teague J, Woffendin H, Garnett MJ, Bottomley W et al.: Mutations
of the BRAF gene in human cancer. Nature 2002, 417:949-954.
39.

Cancer Genome Atlas Network: Genomic classification of
cutaneous melanoma. Cell 2015, 161:1681-1696.
COSMIC (Ref. [4]) and the Cancer Genome Atlas are the most compre-
hensive and constantly updated databases of mutations in cancer.
40. Cancer Genome Atlas Research Network: Integrated genomic
characterization of papillary thyroid, carcinoma. Cell 2014,
159:676-690.
41.

Lavoie H, Therrien M: Regulation of RAF protein kinases in ERK
signalling. Nat Rev Mol Cell Biol 2015, 16:281-298.
A recent review of allosteric and structural mechanisms of RAF activation
driven by dimerization. It presents the time line of more than 3 decades of
research on RAF kinases and their inhibitors
42. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D,
Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D et al.:
Mechanism of activation of the RAF-ERK signaling pathway by
oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
43. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D,
Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ
et al.: B-RAF is a therapeutic target in melanoma. Oncogene
2004, 23:6292-6298.
44. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R,
Gillette S, Kong J, Haass NK et al.: Discovery of a selective
inhibitor of oncogenic B-Raf kinase with potent antimelanoma
activity. Proc Natl Acad Sci U S A 2008, 105:3041-3046.
45. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P:
Vemurafenib: the first drug approved for BRAF-mutant cancer.
Nat Rev Drug Discov 2012, 11:873-886.
46. McGettigan S: Dabrafenib: a new therapy for use in BRAF-
mutated metastatic melanoma. J Adv Pract Oncol 2014, 5:211-
215.
47. Holderfield M, Deuker MM, McCormick F, McMahon M: Targeting
RAF kinases for cancer therapy: BRAF-mutated melanoma
and beyond. Nat Rev Cancer 2014, 14:455-467.
48. Lito P, Rosen N, Solit DB: Tumor adaptation and resistance to
RAF inhibitors. Nat Med 2013, 19:1401-1409.
49. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z,
Lee MK, Attar N, Sazegar H et al.: Melanomas acquire resistance
to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nature 2010, 468:973-977.
50. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P,
Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC et al.:
Dissecting therapeutic resistance to RAF inhibition in
melanoma by tumor genomic profiling. J Clin Oncol 2011,
29:3085-3096.
51. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C,
Moriceau G, Shi H, Atefi M, Titz B, Gabay MT et al.: RAF inhibitor
resistance is mediated by dimerization of aberrantly spliced
BRAF(V600E). Nature 2011, 480:387-390.
52. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L,
Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J et al.:
COT drives resistance to RAF inhibition through MAP kinase
pathway reactivation. Nature 2010, 468:968-972.
53. Johannessen CM, Johnson LA, Piccioni F, Townes A,
Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA,
Root DE et al.: A melanocyte lineage program confers
resistance to MAP kinase pathway inhibition. Nature 2013,
504:138-142.
54. Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P,
McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A et al.:
MED12 controls the response to multiple cancer drugs
through regulation of TGF-beta receptor signaling. Cell 2012,
151:937-950.
55.

Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA,
Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG et al.:
Genome-scale CRISPR-Cas9 knockout screening in human
cells. Science 2014, 343:84-87.www.sciencedirect.com Novel cellular pathways potentially involved in drug resistance were
identified in a genome-scale knockout screen using CRISPR/Cas9 tech-
nology.
56. Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C,
Haanen J, Blank C, Wesseling J, Willems SM et al.: Reversible and
adaptive resistance to BRAF(V600E) inhibition in melanoma.
Nature 2014. advance online publication.
57. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C,
Harshman K, Guipponi M, Bukach O, Zoete V et al.: Exome
sequencing identifies recurrent somatic MAP2K1 and
MAP2K2 mutations in melanoma. Nat Genet 2012, 44:133-139.
58. Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B,
Kris MG, Solit DB, Ladanyi M: MAP2K1 (MEK1) mutations define
a distinct subset of lung adenocarcinoma associated with
smoking. Clin Cancer Res 2015, 21:1935-1943.
59. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA,
Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN
et al.: MAP kinase pathway alterations in BRAF-mutant
melanoma patients with acquired resistance to combined
RAF/MEK inhibition. Cancer Discov 2014, 4:61-68.
60. Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B,
Packman K, Rosen N, Boylan JF, Heimbrook D et al.:
Identification of the MEK1(F129L) activating mutation as a
potential mechanism of acquired resistance to MEK
inhibition in human cancers carrying the B-RafV600E
mutation. Cancer Res 2011, 71:5535-5545.
61. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ,
Hatton C, Chopra R, Oberholzer PA, Karpova MB et al.: MEK1
mutations confer resistance to MEK and B-RAF inhibition.
Proc Natl Acad Sci U S A 2009, 106:20411-20416.
62. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM,
Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM:
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors
overcome acquired resistance to the BRAF inhibitor
GSK2118436 dabrafenib, mediated by NRAS or MEK
mutations. Mol Cancer Ther 2012, 11:909-920.
63. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M,
Demidov LV, Hassel JC, Rutkowski P, Mohr P et al.: Improved
Survival with MEK Inhibition in BRAF-Mutated Melanoma. N
Engl J Med 2012 http://dx.doi.org/10.1056/NEJMoa1203421.
64. Larkin J, Ascierto PA, Dre´no B, Atkinson V, Liszkay G, Maio M,
Mandala` M, Demidov L, Stroyakovskiy D, Thomas L et al.:
Combined vemurafenib and cobimetinib in BRAF-mutated
melanoma. N Engl J Med 2014, 371:1867-1876.
65. Zhao Y, Adjei AA: The clinical development of MEK inhibitors.
Nat Rev Clin Oncol 2014, 11:385-400.
66. Hall-Jackson CA, Goedert M, Hedge P, Cohen P: Effect of SB
203580 on the activity of c-Raf in vitro and in vivo. Oncogene
1999, 18:2047-2054.
67. Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A,
Davies L, Whittaker S, Saturno G, Viros A, Pedersen M et al.:
Paradox-breaking RAF inhibitors that also target SRC are
effective in drug-resistant BRAF mutant melanoma. Cancer
Cell 2015, 27:85-96.
68. Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G,
Zhang J, Lin J, Ewing T, Matusow B et al.: RAF inhibitors that
evade paradoxical MAPK pathway activation. Nature 2015
http://dx.doi.org/10.1038/nature14982.
69. Kholodenko BN: Drug resistance resulting from kinase
dimerization is rationalized by thermodynamic factors
describing allosteric inhibitor effects. Cell Rep 2015,
12:1939-1949.
70. Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, de Stanchina E,
Abdel-Wahab O, Solit DB, Poulikakos PI et al.: BRAF mutants
evade ERK-dependent feedback by different mechanisms that
determine their sensitivity to pharmacologic inhibition. Cancer
Cell 2015, 28:370-383.
71.

Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S,
Rutkoski TJ, Wise S, Chun L, Zhang Y et al.: Inhibition of RAF
isoforms and active dimers by LY3009120 leads to anti-tumorCurrent Opinion in Structural Biology 2016, 41:151–158
158 Multi-protein assemblies in signalingactivities in RAS or BRAF mutant cancers. Cancer Cell 2015,
28:384-398.
Developed a pan-RAF inhibitor that binds all three RAF family members
(A-, C- and BRAF) with very low IC50 and effectively inhibited ERK
activation in RAS or BRAF mutant tumor cells in vitro and in vivo.
72. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M,
Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O et al.:
Heterodimeric JAK-STAT activation as a mechanism ofCurrent Opinion in Structural Biology 2016, 41:151–158 persistence to JAK2 inhibitor therapy. Nature 2012, 489:
155-159.
73. Jambrina PG, Rauch N, Pilkington R, Rybakova K, Nguyen LK,
Kholodenko BN, Buchete NV, Kolch W, Rosta E: Phosphorylation
of RAF kinase dimers drives conformational changes that
facilitate transactivation. Angew Chem Int Ed Engl 2016, 55:
983-986.www.sciencedirect.com
